US 12,378,304 B2
Therapeutic polypeptide
Paul Thomas King, Glen Iris (AU); and Ashley Maurice Buckle, Richmond (AU)
Filed by Paul Thomas King, Glen Iris (AU); and Ashley Maurice Buckle, Richmond (AU)
Filed on Oct. 1, 2024, as Appl. No. 18/903,864.
Application 18/903,864 is a continuation of application No. PCT/AU2024/050430, filed on May 3, 2024.
Claims priority of application No. 2023901357 (AU), filed on May 5, 2023.
Prior Publication US 2025/0092119 A1, Mar. 20, 2025
Int. Cl. C07K 14/81 (2006.01); A61K 38/00 (2006.01); C12N 15/70 (2006.01)
CPC C07K 14/8125 (2013.01) [C12N 15/70 (2013.01); A61K 38/00 (2013.01)] 18 Claims
 
1. An alpha-1 antitrypsin (AAT) polypeptide, comprising:
an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2;
wherein the amino acid sequence includes one, two, or all of the following groups of amino acid substitutions from SEQ ID NO: 2:
S276K, T278E, T323E, D325N, and K327E;
L275F, 1324V, and M358I; and
G99A, Y144W, and Y171A.